Before you draw on owner funds for working capital
1. The decision
The reader is deciding whether to inject personal funds (owner contribution, shareholder loan, drawing on personal savings or personal credit) into the business to cover a working-capital gap.
2. What to verify first
- The nature of the underlying gap. Is the shortfall the timing gap on completed customer invoices, or a structural shortfall (operating loss, demand failure, fixed-cost over-commitment)?
- The expected duration of the gap. A 30 to 60 day timing gap behaves differently from an indefinite operating shortfall. Owner contributions to bridge short timing gaps are recoverable; contributions to fund structural shortfalls are at risk of being lost.
- The tax and accounting treatment. Owner injection can be structured as equity contribution, shareholder loan, or director loan. Each has different tax, accounting, and recovery characteristics in AU and NZ. Improperly documented injections can trigger Division 7A (AU) implications or shareholder-current-account complications.
- The source of the personal funds. Personal savings, redraw from owner-occupied mortgage, personal credit card, personal loan, and family contributions each carry different personal-finance risk profiles.
- The personal-balance-sheet position. What share of personal liquidity does the injection represent? What is the personal-cash buffer remaining after injection?
- The recovery plan. How and when is the owner contribution expected to be repaid? Repayment timing affects the personal cash-flow planning.
3. Hidden costs and structural risks
- Personal-balance-sheet exposure to corporate trading risk. Owner funds injected into the business carry the same risk profile as the business itself. Personal liquidity becomes corporate trading risk.
- Loss of personal buffer. The contribution depletes the personal cash position; subsequent personal events (illness, family emergency, redundancy) become harder to absorb.
- Director and family relationship strain. Owner injections often involve family savings, partner approval, or family co-signature. Repeated injections strain personal relationships.
- Tax classification risk. Mis-classified owner injections in AU can trigger deemed dividend (Division 7A) treatment with tax consequences; in NZ, undocumented shareholder current accounts create their own complications.
- Anchoring risk. A business that has been bridged by owner funds once often expects to be bridged again. The behaviour becomes a substitute for structural financing.
- Opportunity cost on personal capital. Funds deployed into the business cannot be deployed into other personal investments, debt reduction, or retirement savings.
- Subordination behind external creditors. In insolvency, shareholder loans are typically subordinated. The owner is the last to recover.
4. Alternatives in the financing category
The financing question is whether the working-capital gap can be bridged without depleting the personal balance sheet:
- On-demand invoice finance, where customer invoices are funded on issuance, providing cash that keeps the personal balance sheet separate from the corporate working-capital position. Resolves the cash flow timing gap without owner contribution.
- Selective invoice funding, where chosen invoices are funded to cover the specific cash need.
- A bank working-capital facility (noting that bank facilities typically take personal guarantees and family-home security, so the personal-balance-sheet separation is partial).
- Renegotiated supplier or subcontractor terms, addressing the outflow side without injection.
- Retained earnings recycling, if prior profits remain accessible.
5. The funding-readiness check
Scoped to this decision, the business is funding-ready to bridge the gap externally rather than through owner injection when:
- The cash gap is timing-driven on unpaid B2B invoices for completed work.
- The debtors on those invoices are creditworthy commercial entities.
- Standard payment terms (14 to 90 days) apply.
- The accounts receivable ledger sits in a supported accounting platform (Xero, MYOB, QuickBooks Online, Reckon).
- The receivable substance is sufficient to absorb the working-capital requirement.
Outcomes: ready (per-invoice funding closes the cash gap; owner injection is unnecessary), not ready, structural (the underlying gap is not timing-based and owner injection (or restructure) may be the only available bridge), or not ready, temporary (resolve the remediable factor first). See /standards/funding-readiness.
6. When this decision is the right one
- The shortfall is short-duration (under 30 days), small relative to personal liquidity, and a one-off event with a clear repayment timeline.
- External financing is unavailable (the receivable book does not yet exist or does not yet meet eligibility) and the personal balance sheet can absorb the exposure without strain.
- A planned equity injection is part of a deliberate growth-stage capitalisation, not a recurring patch.
- The injection is properly documented as shareholder loan with appropriate tax classification.
- The owner is comfortable with the subordination position and the personal liquidity risk.
7. When this decision is not the right one
- The cash gap is the timing gap on creditworthy B2B receivables. External per-invoice financing matches the gap without depleting personal liquidity.
- The personal balance sheet has limited buffer and the injection would expose the household to material risk on subsequent personal events.
- The injection is a recurring pattern rather than a one-off, indicating that owner funds are substituting for structural financing.
- The underlying business is structurally unprofitable. Injection defers an unresolvable issue and risks personal capital.
- The tax and accounting structure has not been clarified, exposing the injection to mis-classification risk.
8. Version and authority
v1.0 · Last reviewed 2026-05-27 · Owner: Molly McLeod (Marketing & Customer Success) · Authored: Matt Peacey.
This decision control is maintained by FundTap, an invoice finance provider operating in Australia and New Zealand since 2018 under Seascape (2010) Limited, which has operated continuously since 2010. The page is advisory; it does not constitute tax, accounting, or financial advice and should be read alongside professional accounting and tax advice on the specific injection structure and personal position.